X

 

Effective November 29, 2022, Viatris completed the sale of substantially all of its biosimilars portfolio (including related product trademarks) to Biocon Biologics Limited and its subsidiaries (“Biocon”) and the relevant marketing authorizations are in process of being transferred. Viatris Inc. and its subsidiaries (“Viatris”) are not affiliates of Biocon but are providing certain transition services to Biocon following the transaction completion date, such as operating websites (including this site) relating to the biosimilars portfolio on Biocon’s behalf.

How OGIVRI® works

OGIVRI attaches to HER2* receptors on cells. This may stop the cancer cells from growing and multiplying.

how ogivri works

In an international study,

OGIVRI was proven to be as safe and effective

as HERCEPTIN for the treatment of HER2+ metastatic breast cancer.8

What do you need to know?9

HEART PROBLEMS such as congestive heart failure or reduced heart function with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both a trastuzumab product and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with OGIVRI.

As with other trastuzumab treatments (HERCEPTIN®), YOUR HEART WILL BE MONITORED by your cancer care team throughout your treatment journey. This will be done in one of two ways:

Echocardiogram: an ultrasound of your heart

MUGA scan: a moving picture of your heart pumping blood

 

HEART MONITORING

heart monitoring

  • Baseline
    measurement

  • Monitor every 3 months in case of significant cardiac dysfunction withhold treatment and monitor every 4 weeks

  • Monitor every 6 months
    (at least for 2 years)

moniter

  • Immediately prior
    to starting Ogivri

  • While receiving
    Ogivri treatments

  • After completing
    Ogivri treatments

*Normal cells also have HER2, so HER2 targeted therapies like OGIVRI may also affect healthy cells which may cause serious side effects.